Search Results 1081-1090 of 15825 for syphilis

  1. Publications - Jane H. Cerhan, Ph.D., L.P. - Mayo Clinic

    Wefel JS, Deshmukh S, Brown PD, Grosshans DR, Sulman EP, Cerhan JH, Mehta MP, Khuntia D, Shi W, Mishra MV, Suh JH, Laack NN, Chen Y, Curtis AA, Laba JM, ...

  2. LS138D, Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma - Mayo Clinic

    Radioactive substances linked to monoclonal antibodies can bind to cancer cells and give off radiation which may help kill cancer cells. It is not yet known ...

  3. Publications - Moritz Binder, M.D., M.P.H. - Mayo Clinic

    Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, ...

  4. A Study of Erlotinib as a Prevention in Trisomy 7 Positive Primary Sclerosing Cholangitis - Mayo Clinic

    Primary sclerosing cholangitis is a chronic inflammation of the bile ducts of unknown cause and eventually results in cirrhosis of the liver. These patients are ...

  5. Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) - Mayo Clinic

    About this study. Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, ...

  6. Focus Areas - Phospholipid Signaling in Embryonic Development and Human Diseases: Kun Ling - Mayo Clinic Research

    Learn how Dr. Ling's Phospholipid Signaling in Embryonic Development and Human Diseases Lab at Mayo Clinic studies the roles of phosphoinositide species and ...

  7. Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis - Mayo Clinic

    The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will ...

  8. Overview - Division of Clinical Trials and Biostatistics - Mayo Clinic Research

    Learn how Mayo Clinic's Division of Clinical Trials and Biostatistics provides high-value analytical collaborations and research services to investigators.

  9. A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  10. A Study to Evaluate Belinostat and Guadecitabine or ASTX727 to Treat Unresectable and Metastatic Conventional Chondrosarcoma - Mayo Clinic

    Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as guadecitabine, work in ...